UCB cuts price, extends €1bn revolver
Belgian pharmaceutical firm UCB has become the latest western European firm to reduce the cost of its bank debt, after closing an amend-and-extend agreement on a €1bn revolving credit facility.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
